PS- So sorry about your sucky Memphis Grizzlies Dox. LMAO
HIV Transmission and Testing
Am I Infected?
I Just Tested Poz
Living With HIV
Vivir con el VIH
Someone I Care About Has HIV
Meds, Mind, Body & Benefits
Questions About Treatment & Side Effects
Insurance, Benefits Programs & HIV
Mental Health & HIV
Lipodystrophy & Metabolic Problems
Nutrition & HIV
Research News & Studies
« Last post by WillyWump on Yesterday at 05:48:16 PM »
PS- So sorry about your sucky Memphis Grizzlies Dox. LMAO
« Last post by WillyWump on Yesterday at 05:43:44 PM »
So I went to Central MArket to get some fruit today and picked up these amazing rare Autumn Glory Argentinian Apples, and some more Heirloom Navel Oranges..
You people really should try eating better
« Last post by oksikoko on Yesterday at 05:38:04 PM »
I've been taking Stribild daily (one missed dose in January) since December 16. I thought I'd add to this thread, since people search these forums for others' experiences when considering treatments.
Initial thoughts: For the first month or two, I had some weirdishnesses that may or not have been attributed to Stribild but coincided exactly with my having started it.
Side effects: In the last few months, nothing. I take it at 10pm and sleep or don't, but Stribild doesn't seem to have any affect on that. I barely notice I take anything at all anymore except, ugh, the occasional bloatedness. Or rather blOatedness. Is this what women mean when they talk about being bloated monthly? If so, ladies, I apologize for not having bought you more flowers all these years. I still don't eat when I take the pill, and it appears from the literature that this can worsen the problem, meaning, like everything, it's my own damn fault, in which case, "oops".
Rrresults: My VL went from 132,683 to undetectable and CD4 from 920 to 1123 between starting the pill and my second set of labs (despite a rather poor standard of living, I might add). I feel pretty lucky (knock wood), but I gave blood today and will have my third labs back within two weeks. We shall see whether Mr. Stribild has been slacking or if he deserves a present of some kind.
[Edited once to correct a typo in my Stribild start date.]
« Last post by WillyWump on Yesterday at 05:36:40 PM »
Oh sweety I'm sorry
Losing a pet is never ever easy. Ever. and having to put one down is even worse. I feel for you. But you are showing Charlie the greatest love by recognizing his pain and helping him make the transition.
and always remember, Charlie will be waiting for you at Rainbow Bridge
Thank you for your quick answer.
Could you please tell me something.
You did NOT have a risk . Saliva has property's such as proteins and enzymes in it that damages HIV and renders it unable to infect . HIV is sexually acquired from unprotected vaginal and anal intercourse and not in the way you are concerned with .
You do Not need further HIV testing at this point . If this incident was your only concern in the last 3 months then you can rely on the recent HIV test as conclusive proof that you do not have HIV .
Keeping in mind that you didn't have a risk and do not need testing at this time its important to remember that the window period for testing is 6 weeks past any possible exposure and again at 3 months to confirm the results . If you had a risk all of these test you are taking are not doing you any good because its pointless to test before at least 6 weeks .
ALTHOUGH YOU DO NOT NEED FURTHER HIV TESTING AT THIS TIME, anyone who is sexually active should be having a full sexual health care checkup, including but not limited to HIV testing, at least once a year and more often if unprotected intercourse occurs.
If you aren't already having regular, routine checkups, now is the time to start. As long as you make sure condoms are being used for intercourse, you can fully expect your routine HIV tests to return with negative results.
Don't forget to always get checked for all the other sexually transmitted infections as well, because they are MUCH easier to transmit than HIV. Some of the other STIs can be present with no obvious symptoms, so the only way to know for sure is to test.
Use condoms for anal or vaginal intercourse, correctly and consistently, and you will avoid HIV infection. It really is that simple!
Its OK for you to move on and put this behind you now .
There is no reason to be "super scared." Or even scared for that matter.
You absolutely, categorically will NOT get HIV from getting fingered (or fingering anyone). Saliva is NOT infectious. As a matter of fact, saliva contains over a dozen elements which neutralize HIV and render it inert. So to head off any followup questions regarding the guy's oral health, not even if he had HIV, a high viral load, and bleeding gums would it have been a risk in any way.
As a matter of fact, condoms for oral sex are overkill, and I wouldn't be shocked if, along the road, you receive more than a little pushback from people who don't use them for that activity.
Here is the thing - the ONLY confirmed/documented sexual transmission routes for HIV are unprotected anal and vaginal sex. That's it. Use a condom for anal/vaginal sex and you will avoid HIV.
It really is that simple.
*modified for spelling
« Last post by weasel on Yesterday at 05:21:41 PM »
Could you please tell me something.
I hook up with this guy the another night and we essentially kissed, oral sex was with condom and anal sex was with condom too (although full penetration did not occur, and the guy simply gave up the penetration and ended up masturbating alone... I was super tight... first time )...
But something is really getting me nervous em super preoccupied... he fingered me vigorously and used his saliva as lube... my anal area is kind hurt now... is there any risk of infection? I already had a test done, and I'm gonna do another one in two months and 8 days... I'm super scared... please any comments to this?
Research News & Studies / HIV Therapy Just Got Easier: Fewer Drugs May Be Needed For Treatment-Experienced« Last post by aaware72 on Yesterday at 04:48:34 PM »
My doctor is out of Massachusetts General Hospital. When I was there yesterday I was reading the ACTG March 2013 research updates and came across this:
A5242 OPTIONS Results: Fewer Drugs May Be Needed For Treatment-Experienced
Trial proves, for the first time, that treatment-experienced patients can leave out this class of medication, known as nucleoside reverse transcriptase inhibitors (NRTI), as part of the regimen. These results could change treatment guidelines, lessen side effects and increase adherence rates, the researchers say.
Tashima and colleagues presented the results from the 48-week study at the annual Conference for Retroviruses and Opportunistic Infections (CROI) in Atlanta on March 6.
“We are so comfortable clinically with the NRTI class that we think we must always use at least one drug from this class in treatment. However, some patients have developed within-class resistance, making the NRTIs less effective overall. Therefore, drugs from this class may not be needed if the new treatment plan contains more effective medications,” said Tashima, who also leads ACTG’s clinical research site at The Miriam Hospital.
“There were a few new drugs coming out at the same time and we decided to turn the question around. Instead of having patients take their current medications from the NRTI class as well as these new drugs from different classes, we asked half of the study participants to add NRTIs and half of them to leave out NRTIs from their new treatment plan. We were able to take the usual study paradigm and turn it around,” she added.
Treatment-experienced patients can develop resistance to therapy due to poor adherence, said Richard Haubrich, MD, the study’s co-chair and professor of medicine at University of California at San Diego. Designing a treatment plan using new drugs from new classes and omitting NRTIs leads to fewer pills, and hopefully, better adherence.
“There are several options for treatment naïve patients, but not as many for treatment-experienced. The HIV research field accepted that nucleosides would be an important component for multiple class-experienced patients,” said Haubrich. “However, our results were very clear. We can safely exclude NRTIs, giving physicians a new paradigm for ART prescription in clinic and potentially changing treatment guidelines.”
To ensure eliminating NRTIs from their treatment regimen would not be detrimental for viral suppression, investigators used a web utility to review each of the 413 study participants’ study records to determine optimal treatment plans. This tool allowed all of the study’s investigators to consult together on each study participant, offering the best plan for treatment.
The OPTIONS Trial, also called A5241, included ACTG sites from around the country as well as sites from the International Maternal Pediatric Adolescent AIDS Clinical Trials group and the Adolescent Medicine Trials Network. Study volunteers needed to be at least 16 years old and show treatment experience or resistance to their current HIV medications. Most of the A5241 participants had been on ART for 10 years or more.
Traditional antiretroviral therapy consists of medications from the nucleoside reverse transcriptase inhibitor class, including tenofovir, azidothymidine and lamivudine. The new medications studied included darunavir and tipranavir from the protease inhibitor class of HIV medications, maraviroc from the CCR5 antagonist class, raltegravir from the integrase inhibitor class, etravirine from the non-nucleoside reverse transcriptase inhibitors class and enfuvirtide an injectable drug from the fusion inhibitor class.
Patients will continue on study for a total of 96 weeks to ensure virologic suppression is maintained.
“There is no question that the results show what we had set out to prove – a treatment-experienced patient will not lose virologic suppression by omitting NRTIs,” said Tashima. “We are so excited to show this data.”
This research was supported by the U.S. Department of Health and Human Services (DHHS), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) and the Division of AIDS (DAIDS) under awards 5U01AI069472 and UM1-A1068636.
The principal affiliation of Karen Tashima, MD, is The Miriam Hospital (a member hospital of the Lifespan health system in Rhode Island). Tashima is also a professor of medicine at The Warren Alpert Medical School of Brown University.
The AIDS Clinical Trials Group (ACTG) Network’s Leadership and Operations Center (LOC) is based at Brigham and Women’s Hospital in Boston. The ACTG Network’s mission is to develop and conduct scientifically rigorous translational research and clinical trials to (1) investigate the viral and immune pathogenesis of HIV-1 infection and its complications; (2) evaluate novel drugs and strategies for treating HIV-1 infection; (3) evaluate interventions and strategies to treat and prevent HIV-related co-infections and co-morbidity, and; (4) publish and disseminate results to improve care, and reduce or eliminate morbidity and mortality associated with HIV-1 infection and its complications. The Network has 73 research sites around the world, including 50 domestically and 23 abroad.
Retrieved on May 23, 2013, from, http://www.miriamhospital.org/wtn/Page.asp?PageID=WTN000386
Terms of Membership for these forums
Smart + Strong® is a registered trademark of CDM Publishing, LLC.